A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.
2014
Background
Currently, there are no direct comparisons of apixaban and rivaroxaban, two new oral direct factor Xa inhibitors approved for management of thromboembolic disorders.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
22
References
59
Citations
NaN
KQI